Welcome to our dedicated page for CHARLES RIVER LABORATORIES INTERNATIONAL SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CHARLES RIVER LABORATORIES INTERNATIONAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CHARLES RIVER LABORATORIES INTERNATIONAL's regulatory disclosures and financial reporting.
Charles River Laboratories (CRL) insider update: Interim CFO Michael G. Knell reported an acquisition of 2,926 shares of common stock at $170.88 on 11/06/2025 (transaction code A), increasing his beneficial ownership to 13,460 shares, held directly.
The filing notes these are restricted stock units with a two-step vesting schedule: 50% vest on November 6, 2026 and the remaining 50% on November 6, 2027.
Charles River Laboratories (CRL) reported Q3 2025 results. Total revenue was $1,004,852,000, slightly below last year’s $1,009,763,000. Service revenue decreased to $808,042,000, while product revenue rose to $196,810,000. Operating income increased to $133,799,000, but higher tax expense and unfavorable other income led to net income attributable to CRL of $54,422,000 versus $69,657,000 a year ago. Diluted EPS was $1.10 compared with $1.33.
By segment, Q3 revenue was: DSA $600,685,000; RMS $213,474,000; and Manufacturing $190,693,000. Operating income improved in RMS and was roughly flat in Manufacturing, while DSA softened slightly. The company changed useful lives for certain assets, reducing depreciation and increasing EPS by about $0.07 in the quarter and $0.21 year‑to‑date.
Year to date, revenue was $3,021,155,000 with diluted EPS of $2.65. Operating cash flow reached $590,126,000, funding $130,202,000 of capex and $360,577,000 of share repurchases. CRL repurchased 2.1 million shares for $350,000,000 and approved a new $1.0 billion authorization on October 29, 2025.
Charles River Laboratories International, Inc. furnished an update on its business by issuing a press release with financial results for the third quarter ended September 27, 2025. The press release was provided as Exhibit 99.1 and contains forward‑looking statements under the Private Securities Litigation Reform Act of 1995.
The information under Item 2.02 is being furnished and is not deemed filed under the Exchange Act, except as expressly incorporated by reference in future filings.
Charles River Laboratories International, Inc. filed an amendment to a prior report about its leadership change to add details on interim Chief Financial Officer Michael G. Knell’s compensation. Effective September 28, 2025, his annual base salary will be increased to $500,000. Starting October 1, 2025, he will also receive a $10,000 monthly cash payment during his term as interim Chief Financial Officer.
In addition, the Compensation Committee approved a one-time grant of restricted stock units with a grant value of $500,000 in the company’s common stock, to be granted on November 6, 2025. Half of these units will vest on the first anniversary of the grant date and the remaining half on the second anniversary, aligning part of his compensation with the company’s long‑term performance.
Charles River Laboratories International, Inc. reported that Chief Financial Officer Flavia H. Pease has informed the company she will resign as Corporate Executive Vice President and CFO, effective September 29, 2025. The company states that her decision is not due to any disagreements regarding financial statements, internal controls, operations, policies, or practices.
In connection with her departure, the Board has appointed Michael G. Knell, currently Corporate Senior Vice President and Chief Accounting Officer, to serve as interim Chief Financial Officer and principal financial officer, effective upon Ms. Pease’s departure and until a permanent successor is named. Mr. Knell has been with the company since 2017 and is a Certified Public Accountant with prior senior finance and audit experience. The company also issued a press release on September 16, 2025 announcing these changes.
Charles River Laboratories (CRL) Form 144 shows a proposed sale of 400 shares of common stock to be executed through UBS Financial Services on 08/22/2025 with an indicated aggregate market value of $61,000. The securities were originally acquired on 01/27/2023 as Performance Stock Units from Charles River Laboratories, with 8,379 units reported as acquired and payment in cash on 05/13/2025. The filer also reported two recent sales in August 2025: 800 shares sold on 08/18/2025 for $126,054 and 400 shares sold on 08/08/2025 for $5,991. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Joseph W. LaPlume, an officer and director at Charles River Laboratories (CRL) serving as EVP, Corporate Strategy & Development, reported an open-market sale of 800 shares of CRL common stock on 08/18/2025 at a reported price of $157.60 per share. After the transaction he beneficially owned 24,116 shares. The Form 4 was signed on 08/20/2025. The filing discloses a single non-derivative sale and no derivatives or additional transactions.
Charles River Laboratories (CRL) Form 144 discloses a proposed sale of 22,500 shares of common stock through Merrill Lynch on or about 08/18/2025 with an aggregate market value of $3,420,000. The notice identifies the seller as Richard Wallman and shows prior acquisitions by the seller including RSU vesting from 2017–2019 and multiple open-market purchases in June–July 2025 totaling 15,000 shares. The filing also reports recent sales by the same person in the past three months: 4,000 shares on 06/23/2025 for $550,000 and 8,500 shares on 07/21/2025 for $1,275,000. The filer certifies no undisclosed material adverse information.
Form 144 notice for Charles River Laboratories (CRL) discloses a proposed sale of 800 shares of common stock through UBS Financial Services (Weehawken, NJ) with an aggregate market value of $125,600. The shares represent part of outstanding common stock of 49,120,000 and an approximate sale date of 08/18/2025 on the NYSE. The filing shows the shares were acquired as Performance Stock Units on 01/27/2023 from Charles River Laboratories and that payment at sale is expected in cash. The filer previously sold 400 shares on 08/07/2025 for $59,991. The notice includes the customary attestation that the seller is unaware of undisclosed material adverse information.
Nomura Holdings, Inc. reports beneficial ownership of 2,681,669 shares of Charles River Laboratories common stock, representing 5.4% of the outstanding class. The total includes 473,087 shares held by Nomura Global Financial Products, Inc. (NGFP), 1,096,182 shares held by Nomura Securities International, Inc. (NSI), and call options exercisable within 60 days covering 1,112,400 shares (1,100,000 by NGFP and 12,400 by NSI). The percent is calculated using 49,209,000 shares outstanding as of June 28, 2025, per the issuer's quarterly report. The filing states these holdings were acquired and are held in the ordinary course of business.